CJC-1295 vs Ipamorelin: Research Overview

CJC-1295 vs Ipamorelin: the short answer

The core difference reported in published laboratory research is the receptor each compound targets. CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) and is studied for binding at the GHRH receptor on anterior pituitary cells. Ipamorelin is a synthetic pentapeptide classed as a growth-hormone secretagogue that is studied as a selective agonist of the ghrelin receptor, also written as GHS-R1a. In short, the two molecules act on two different receptor systems that both feed into the same pituitary pathway in preclinical models.

Because they engage separate receptors, research literature often describes them as complementary tools in experimental models rather than interchangeable ones. This article compares what the published pharmacology says about each, strictly for laboratory research context. Nothing here is a protocol, a recommendation, or a statement of any effect in people. These are research-use-only laboratory compounds and are not for human or animal use.

What CJC-1295 is in the research literature

CJC-1295 is characterised in the literature as a modified analogue of the first 29 amino acids of human GHRH. The parent sequence, GHRH (1-29), is the biologically active fragment of natural GHRH. CJC-1295 carries amino-acid substitutions intended to increase stability against enzymatic breakdown compared with the unmodified fragment, which is a frequent subject of structure-activity studies.

Mechanistically, research describes CJC-1295 as acting at the GHRH receptor expressed on somatotroph cells of the anterior pituitary. This is the same receptor family that endogenous GHRH is reported to engage in the published endocrinology literature. The comparison point to keep in mind is that CJC-1295 is a GHRH-pathway molecule, which distinguishes it structurally and pharmacologically from ghrelin-pathway compounds.

CJC-1295 with DAC versus no-DAC (mod GRF 1-29)

A key distinction in the CJC-1295 literature is the presence or absence of a Drug Affinity Complex, abbreviated DAC. The DAC is a chemical group described as allowing the peptide to bind reversibly to albumin, a carrier protein in blood. Studies report that this albumin binding substantially lengthens the molecule's circulating half-life in experimental models.

The version without DAC is more precisely named modified GRF (1-29), often written mod GRF 1-29. It retains stabilising substitutions but omits the albumin-binding complex, and research describes it as having a much shorter duration of action that more closely resembles the transient profile of natural GHRH. The two forms therefore show different reported pharmacokinetic profiles in study models, which is an important detail when reading or comparing the literature.

• CJC-1295 with DAC: albumin-binding complex, reported extended half-life, sustained profile in models.
• CJC-1295 without DAC (mod GRF 1-29): no albumin complex, reported shorter half-life, more transient profile in models.
• Both are described as GHRH-receptor-targeting analogues, not ghrelin-receptor compounds.

What Ipamorelin is in the research literature

Ipamorelin is described in published research as a synthetic pentapeptide, meaning a chain of five amino acids, belonging to the growth-hormone secretagogue class. It was first reported in the scientific literature in the late 1990s and is studied as a selective agonist of the ghrelin receptor, GHS-R1a.

The word selective is central to how the literature characterises Ipamorelin. Early studies described it as among the first secretagogues in its class reported to act on the growth-hormone pathway in preclinical models without the marked rises in adrenocorticotropic hormone (ACTH), cortisol and prolactin that were reported for some earlier growth-hormone-releasing peptides such as GHRP-6 and GHRP-2. This reported selectivity profile is one of the most frequently cited features of Ipamorelin in comparison studies.

Mechanism side by side

Placing the two molecules next to each other clarifies the comparison. Both are studied in connection with the anterior pituitary, but they approach it through different receptors and are often examined together in research precisely because their pathways differ.

The receptor-level distinction is the single most useful thing to understand when reading comparative literature on these two compounds. One is a GHRH-pathway analogue and the other is a ghrelin-pathway agonist.

• Compound class: CJC-1295 is a GHRH analogue; Ipamorelin is a growth-hormone secretagogue.
• Studied receptor target: CJC-1295 at the GHRH receptor; Ipamorelin at the ghrelin receptor (GHS-R1a).
• Structure: CJC-1295 is based on a 29-amino-acid GHRH fragment; Ipamorelin is a 5-amino-acid pentapeptide.
• Reported selectivity note: Ipamorelin literature emphasises minimal reported effect on cortisol and prolactin in studies.
• Duration variants: CJC-1295 exists as DAC and no-DAC forms with different reported half-lives; Ipamorelin is a single defined pentapeptide.

Regulatory status in Australia

Both compounds are tightly regulated in Australia and neither is an approved medicine. Reporting on the Australian framework indicates that CJC-1295 and Ipamorelin are not entered on the Australian Register of Therapeutic Goods (ARTG) as registered products, and that they appear as prescription-only (Schedule 4) entries in the Poisons Standard, with further restrictions described under the Standard's appendices. The Therapeutic Goods Administration has also stated that importing, advertising, manufacturing and supplying unapproved peptide products can be unlawful.

Readers should treat any mention of these compounds as educational and research-focused only. If you want the Australian legal framing in more detail, see the linked overview below. For anti-doping context, both GHRH analogues and growth-hormone secretagogues fall within the World Anti-Doping Agency category S2 (peptide hormones, growth factors and related substances), which is prohibited at all times under WADA rules.

Is CJC-1295 legal in Australia? WADA banned peptides explained

Why quality and identity matter in research settings

In any laboratory research context, the identity and purity of a reference compound determine whether results are meaningful. Because CJC-1295 exists in multiple forms, including DAC and no-DAC variants, mislabelling can easily confound a comparison between the two molecules discussed here. The same applies to verifying that a labelled Ipamorelin sample is in fact the defined pentapeptide.

Independent analytical methods are the standard way researchers confirm what a vial actually contains. The linked guides below cover how purity testing is reported and how to think about product identity in a research-use-only setting.

Peptide purity testing (HPLC) explained

Summary of the comparison

To recap neutrally: CJC-1295 and Ipamorelin are two different synthetic peptides studied in connection with the pituitary but acting through two distinct receptor systems. CJC-1295 is a GHRH-receptor analogue available in longer-acting DAC and shorter-acting no-DAC (mod GRF 1-29) forms. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist pentapeptide noted in the literature for a reported lack of marked cortisol and prolactin elevation relative to some earlier secretagogues.

Both are unapproved in Australia, appear as scheduled entries in the Poisons Standard, are absent from the ARTG as registered medicines, and sit within WADA category S2. This overview is provided solely for educational and laboratory research purposes and makes no claims about effects in humans or animals.